TransCode Therapeutics Appoints Dr. Michel Janicot as Senior Development Officer to Advance Oncology Pipeline

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has appointed Dr. Michel Janicot as consultant Senior Development Officer, bringing more than 35 years of global oncology drug-development experience to support the advancement of the company's therapeutic pipeline. Dr. Janicot, founder of JMi ONConsulting and former senior leader at Rhône-Poulenc Rorer and Janssen, brings deep expertise in RNA biology, preclinical strategy, translational medicine, and early clinical development to his new role at TransCode.

The appointment comes at a critical juncture for TransCode as the company progresses its investigational oncology programs toward later-stage clinical trials. Dr. Janicot will guide TransCode's strategic research and development initiatives, providing valuable leadership as the company advances its RNA-based therapeutic candidates. His extensive background in both large pharmaceutical companies and consulting positions him to contribute significantly to TransCode's development strategy.

TransCode is a clinical-stage oncology company focused on treating metastatic disease through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. This strategic appointment strengthens TransCode's leadership team as it works to advance TTX-MC138 and Seviprotimut-L through the development pipeline.

The addition of Dr. Janicot's expertise is particularly valuable given his background in RNA biology and translational medicine, areas central to TransCode's therapeutic approach. His experience spans multiple aspects of drug development, from preclinical strategy through early clinical development, making him well-suited to help navigate the complex regulatory and scientific challenges of advancing novel RNA therapeutics. Investors can access the latest news and updates relating to RNAZ in the company's newsroom at https://ibn.fm/RNAZ.

TransCode's portfolio includes other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery, potentially unlocking therapeutic access to various novel genetic targets relevant to treating multiple cancer types. The full press release detailing Dr. Janicot's appointment and his background can be viewed at https://ibn.fm/TAIIy. This strategic hire represents a significant step in strengthening TransCode's development capabilities as the company works to bring innovative RNA-based cancer treatments to patients facing metastatic disease.